Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet

A combination of olanzapine and samidorphan (OLZ/SAM) was recently approved by the US Food and Drug Administration for treatment of patients with schizophrenia or bipolar I disorder. The effects of moderate hepatic impairment on the pharmacokinetics (PKs) of olanzapine and samidorphan after a single...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lei, Barter, Zoe, von Moltke, Lisa, Rowland Yeo, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452299/
https://www.ncbi.nlm.nih.gov/pubmed/34185436
http://dx.doi.org/10.1002/psp4.12675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452299/
https://www.ncbi.nlm.nih.gov/pubmed/34185436
http://dx.doi.org/10.1002/psp4.12675

Ejemplares similares